Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients

Table 2 Comparison of serum lipid profile before and after 1 year of anti-viral therapy either tenofovir alafenamide or entecavir

Characteristic	TAF, n = 214, statistic	P value1	ETV, n = 122, statistic	P value1	P value2
Pre-Tx TCHO in mmol/L	4.51 ± 0.93	0.001	4.41 ± 1.03	0.275	0.376
Post-Tx TCHO in mmol/L	4.67 ± 0.90		4.36 ± 1.05		0.006
Pre-Tx TG in mmol/L	1.25 ± 0.67	0.014	1.33 ± 0.75	0.052	0.35
Post-Tx TG in mmol/L	1.37 ± 0.81		1.24 ± 0.61		0.126
Pre-Tx HDL in mmol/L	1.32 ± 0.40	0.794	1.26 ± 0.40	0.879	0.246
Post-Tx HDL in mmol/L	1.32 ± 0.36		1.27 ± 0.41		0.285
Pre-Tx LDL in mmol/L	3.12 ± 0.90	0.785	3.06 ± 1.01	0.078	0.543
Post-Tx LDL in mmol/L	3.14 ± 0.92		3.15 ± 1.00		0.906
Pre-Tx NAFLD	75 (35.05)	0.125	32 (26.23)	1	0.122
Post-Tx NAFLD	70 (32.71)		31 (25.41)		0.16

¹Comparing the pretreatment and post-treatment variables (paired) in each therapy type.

²Comparing the same variable (either pretreatment or post-treatment) according to type of therapy. ETV: Entecavir; HDL: High density lipoprotein; LDL: Low-density lipoprotein; NAFLD: Nonalcoholic fatty liver disease; TAF: Tenofovir alafenamide; TCHO: Total cholesterol; TG: Triglycerides; Tx: Treatment.